Glenmede Trust’s Travere Therapeutics TVTX Stock Holding History

Glenmede Trust’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-721	Closed	-$13K	–	2194
2020 Q3	$13K	Hold	721	–	–	﹤0.01%	1788
2020 Q2	$14K	Sell	721 -94	-12%	-$1.5K	﹤0.01%	1747
2020 Q1	$11K	Hold	815	–	–	﹤0.01%	2399
2019 Q4	$11K	Buy	815 +721	+767%	+$9.21K	﹤0.01%	2399
2019 Q3	$1	Hold	94	–	–	﹤0.01%	2948
2019 Q2	$1	Hold	94	–	–	﹤0.01%	2988
2019 Q1	$2	Hold	94	–	–	﹤0.01%	2856
2018 Q4	$2	Buy	+94	New	+$2.34K	﹤0.01%	2798

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust's TVTX Position: Q4 2020 in Review

Glenmede Trust sold out of Travere Therapeutics (TVTX) in Q4 2020, closing a stake of 721 shares — an estimated $13K sold.

Glenmede Trust first reported a position in TVTX in Q4 2018 and held it in 8 quarters. The position peaked at $14K in Q2 2020. 138 funds tracked by Wall St. Rank hold TVTX as of Q4 2020.

Glenmede Trust reported no remaining Travere Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 721 Travere Therapeutics shares in Q4 2020, an estimated $13K.
Glenmede Trust first reported a position in Travere Therapeutics in Q4 2018 and held it in 8 quarters.
Glenmede Trust's Travere Therapeutics position peaked at $14K in Q2 2020.
138 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.